Latest Press Releases
- Adaptive Phage Therapeutics Announces “The AMR RAPID™ Challenge” for the Infectious Disease Research Community: Find a Bacteria Resistant to APT’s Investigational Phage Bank
- Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis
- Adaptive Phage Therapeutics Appoints Rob Casper as Vice President of Clinical Operations
- Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund
- Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study
- Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases
- Adaptive Phage Therapeutics Appoints Michele Wales, Ph.D., J.D., as Chief Legal Officer
- Adaptive Phage Therapeutics Adds Jesse L. Goodman, M.D., M.P.H., to its Board of Directors
- Adaptive Phage Therapeutics Highlights the Publication of a Case Study of Investigational Phage Therapy for an Antibiotic-Resistant Bacterial Infection in a Child
See all press releases